Page 2 - Patrick Wingrove News Today

By Patrick Wingrove (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due to poor U.S. sales of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira. The German drugmaker said it planned ...

Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due to poor U.S. sales of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira. The German drugmaker said it planned to reduce its customer-facing teams in favor of a hybrid in-person and virtual sales model by June 30, in large part because pharmacy benefit managers (PBMs) had kept branded Humira on their lists of medicines for reimbursement. That choice has led to less uptake of biosimila...

Four doses of Eli Lilly's diabetes drug Mounjaro would remain in tight supply through 2024 due to soaring demand, the U.S. Food and Drug Administration's website...

The regulator noted limited availability of 7.5, 10, 12.5, and 15 milligram doses through April, while lower doses were listed as "available". The FDA had previously said that three doses would have limited availability through early March.

Eli Lillys blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well as Novo Nordisks rival medicines Ozempic and Wegovy are being studied to see whether they can improve health...

The World Health Organization has said global shortages of these drugs is linked to rising reports of suspected counterfeits. Last week, U.S. FDA head Robert Califf said there were likely more cases of online sales of fake obesity drugs than reported.

Healthcare providers across the United States are struggling to get paid following the week-long ransomware outage at a key tech unit of UnitedHealth Group, with some smaller providers saying they... -February 29, 2024 at 06:09 am EST - MarketScreener

(Reuters) -Moderna on Thursday reported a surprise fourth-quarter profit, helped by cost cutting and some deferred payments, and the vaccine maker set out a commercial roadmap for its experimental respiratory syncytial virus (RSV) shot. Moderna posted a profit of $217 million, or 55 cents a share, for the quarter. Moderna Chief Financial Officer James Mock in an interview said the company beat its own forecast because of unexpected deferred revenue of $600 million and cost savings of around $3...

(Reuters) -Eli Lilly on Tuesday forecast 2024 profit above Wall Street estimates on soaring demand for its recently approved weight-loss drug, and said the treatment helped reduce symptoms of a common, difficult to treat fatty liver disease in a mid-stage trial. Shares of the Indianapolis-based drugmaker jumped nearly 5% in premarket trading after gaining about 11% in January, making Lilly the eighth largest company in the U.S. by market capitalization and most valuable healthcare company.

Eli Lilly's blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well Novo Nordisk's rival medicines Ozempic and Wegovy are being studied to see whether they can improve health in other ways. Lilly on Tuesday said Zepbound had been shown in a mid-stage trial to help reduce symptoms of a fatty liver disease. * A study by the University of Copenhagen's Psychiatric Centre Rigshospitalet is investigating whether semaglutide, sold as Novo's Wegovy and Ozempic,...